Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations.
Plasma coenzyme Q10 (CoQ10) response to oral ingestion of various CoQ10 formulations was examined. Both total plasma CoQ10 and net increase over baseline CoQ10 concentrations show a gradual increase with increasing doses of CoQ10. Plasma CoQ10 concentrations plateau at a dose of 2400 mg using one specific chewable tablet formulation. The efficiency of absorption decreases as the dose increases. About 95% of circulating CoQ10 occurs as ubiquinol, with no appreciable change in the ratio following CoQ10 ingestion. Higher plasma CoQ10 concentrations are necessary to facilitate uptake by peripheral tissues and also the brain. Solubilized formulations of CoQ10 (both ubiquinone and ubiquinol) have superior bioavailability as evidenced by their enhanced plasma CoQ10 responses.
Bhagavan
Hemmi N
HN
Tishcon Corporation, 30 New York Avenue, P.O. Box 331, Westbury, NY 11590, USA. hemmi@tishcon.com
Chopra
Raj K
RK
D000284:Administration, Oral; D000328:Adult; D000818:Animals; D001921:Brain / Q000378:metabolism; D002626:Chemistry, Pharmaceutical / Q000379:methods; D002648:Child; D002986:Clinical Trials as Topic; D003067:Coenzymes / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism; D006801:Humans; D008954:Models, Biological; D010084:Oxidation-Reduction; D013607:Tablets; D013997:Time Factors; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000737:chemistry / Q000378:metabolism
D003067:Coenzymes; D013607:Tablets; D014451:Ubiquinone; C024989:coenzyme Q10; C003741:ubiquinol